He Miao, Liu Haina, Cao Jingyi, Wang Qian, Xu Haiting, Wang Yufeng
Department of Nuclear Medicine, Xuzhou Cancer Hospital, Jiangsu Province, Xuzhou, China.
Department of Urology, Xuzhou Cancer Hospital, Jiangsu Province, Xuzhou, China.
Oncotarget. 2017 Nov 1;8(62):105458-105462. doi: 10.18632/oncotarget.22246. eCollection 2017 Dec 1.
This study analyzed Tcm-MDP bone scans and investigated factors influencing early-stage castration resistance in prostate cancer (CRPC) patients with bone metastasis. We retrospectively analyzed clinical data from 92 patients with bone metastatic prostate cancer treated with maximal androgen blockade. Patients were imaged with Tcm-MDP bone scan to detect metastases, and prostate specific antigen (PSA) values were measured regularly. Before treatment, 464 total bone metastases were detected in the 92 patients, with pelvic bone metastases accounting for about 30.6% of the total. After combined androgen blockade treatment, median CRPC occurrence time was 23 months. A longer time to reach the lowest PSA value was an independent predictor of early-onset CRPC (occurrence <1 year after treatment). Our findings suggest that Tcm-MDP bone scans are useful for diagnosing prostate cancer bone metastasis and grading. Patients with Gleason scores>8, higher PSA values after treatment, and shorter times to reach the lowest PSA value had poorer responses to combined androgen blockade treatment.
本研究分析了锝-亚甲基二膦酸盐（Tc-MDP）骨扫描，并调查了影响骨转移前列腺癌（CRPC）患者早期去势抵抗的因素。我们回顾性分析了92例接受最大雄激素阻断治疗的骨转移前列腺癌患者的临床资料。对患者进行Tc-MDP骨扫描以检测转移灶，并定期测量前列腺特异性抗原（PSA）值。治疗前，92例患者共检测到464处骨转移灶，其中骨盆骨转移灶约占总数的30.6%。联合雄激素阻断治疗后，CRPC的中位发生时间为23个月。达到最低PSA值的时间较长是早期CRPC（治疗后<1年发生）的独立预测因素。我们的研究结果表明，Tc-MDP骨扫描有助于诊断前列腺癌骨转移和分级。Gleason评分>8、治疗后PSA值较高且达到最低PSA值的时间较短的患者对联合雄激素阻断治疗的反应较差。
